The vaccine uses synthetic mRNA to instruct cells to produce a harmless fragment of the virus.

The researchers sequenced the mRNAs extracted from the tumor samples to identify gene expression changes.

Researchers compared the stability of different mrnas to optimize vaccine design.

The lab's recent mrna sequencing revealed unexpected splice variants.